黄芪甲苷Ⅳ通过重塑肠道菌群与短链脂肪酸调节脓毒症肠道巨噬细胞M1/M2极化
该研究在小鼠盲肠结扎穿孔脓毒症模型中,于造模前以黄芪甲苷Ⅳ灌胃预处理7天,观察肠道固有层巨噬细胞M1/M2极化、肠道屏障、NLRP3炎症小体、16S rRNA菌群及粪便短链脂肪酸变化。结果显示盲肠结扎穿孔促进M1极化、激活NLRP3、菌群失衡并降低乙酸、丙酸、丁酸水平;黄芪甲苷Ⅳ逆转M1/M2极化、减轻炎症与屏障损伤、降低NLRP3表达、恢复菌群多样性并升高丁酸。粪菌移植或外源丁酸补充可模拟上述获益;体外Caco-2与THP-1共培养中丁酸减轻LPS与干扰素γ所致损伤,而NLRP3基因过表达可消除丁酸的保护作用。作者认为其机制可能为恢复肠道菌群与短链脂肪酸以抑制NLRP3炎症小体活化。
要点
- 小鼠盲肠结扎穿孔后肠道固有层巨噬细胞M1极化增强,伴细胞因子异常释放与肠屏障功能障碍,M1巨噬细胞中NLRP3炎症小体活化。
- 黄芪甲苷Ⅳ于造模前灌胃预处理7天,可逆转肠道固有层巨噬细胞M1/M2极化、减轻肠道炎症与屏障损伤、降低NLRP3表达。
- 盲肠结扎穿孔后粪便乙酸、丙酸、丁酸水平下降,黄芪甲苷Ⅳ恢复肠道菌群多样性并升高丁酸水平。
- 粪菌移植或外源丁酸补充可模拟黄芪甲苷Ⅳ的获益;体外丁酸减轻LPS与干扰素γ所致THP-1 M1极化与Caco-2屏障损伤,NLRP3基因过表达可消除该保护作用。
适用人群与场景
- 小鼠盲肠结扎穿孔脓毒症模型,造模前接受黄芪甲苷Ⅳ灌胃预处理7天。
- 体外Caco-2与THP-1共培养模型,以LPS与干扰素γ刺激。
处置流程与药物剂量
- 小鼠于盲肠结扎穿孔前以黄芪甲苷Ⅳ灌胃预处理7天(原文未写明剂量与频次)。
- 粪菌移植或外源丁酸补充可模拟黄芪甲苷Ⅳ的获益(原文未写明剂量与途径)。
- 体外Caco-2与THP-1共培养中给予丁酸,可减轻LPS与干扰素γ所致THP-1 M1极化、Caco-2屏障损伤、细胞因子异常释放及THP-1细胞高NLRP3炎症小体表达(原文未写明丁酸浓度)。
研究设计与关键结果
- 小鼠实验:盲肠结扎穿孔促进肠道固有层巨噬细胞M1极化,伴细胞因子异常释放与肠屏障功能障碍,M1巨噬细胞中NLRP3炎症小体活化,16S rRNA测序显示肠道菌群失衡。
- 盲肠结扎穿孔后粪便乙酸、丙酸、丁酸水平下降;黄芪甲苷Ⅳ逆转M1/M2极化、减轻肠道炎症与屏障损伤、降低固有层巨噬细胞NLRP3表达、恢复肠道菌群多样性并升高丁酸水平。
- 粪菌移植或外源丁酸补充可模拟黄芪甲苷Ⅳ的上述获益。
- 体外Caco-2与THP-1共培养:LPS与干扰素γ引起THP-1 M1极化、Caco-2屏障损伤、细胞因子异常释放及THP-1细胞高NLRP3表达,丁酸给药可减轻上述改变;THP-1中NLRP3基因过表达可消除丁酸的保护作用。
证据类型、等级与局限
- 证据类型:小鼠在体实验与体外细胞实验(Caco-2与THP-1共培养)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,黄芪甲苷Ⅳ可通过调节肠道巨噬细胞M1/M2极化改善脓毒症所致肠道炎症与屏障功能障碍,其机制可能为恢复肠道菌群与短链脂肪酸以抑制NLRP3炎症小体活化。
- 上述结果为小鼠与体外实验,原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
M1 macrophage-mediated inflammation is critical in sepsis. We previously found the protective role of astragaloside intravenous (AS-IV) in sepsis-associated gut impairment, whose specific mechanism remains unknown. Gut microbiota modulates gut homeostatic balance to avoid excessive inflammation. Here, we aimed to investigate effects of AS-IV on gut macrophages polarization and potential roles of gut microbiota and short chain fatty acids (SCFAs) in septic gut damage. Mice were pretreated by AS-IV gavage for 7 days before cecal ligation and puncture. M1 polarization of gut lamina propria macrophages (LpMs) was promoted by cecal ligation and puncture, accompanied by abnormal cytokines release and intestinal barrier dysfunction. NLRP3 inflammasome was activated in M1 LpMs. 16S rRNA sequencing demonstrated gut microbiota imbalance. The levels of acetate, propionate, and butyrate in fecal samples decreased. Notably, AS-IV reversed LpMs M1/M2 polarization, lightened gut inflammation and barrier injury, reduced NLRP3 inflammasome expression in LpMs, restored the diversity of gut microbiome, and increased butyrate levels. Similarly, these benefits were mimicked by fecal microbiota transplantation or exogenous butyrate supplementation. In Caco-2 and THP-1 cocultured model, LPS and interferon γ caused THP-1 M1 polarization, Caco-2 barrier impairment, abnormal cytokines release, and high NLRP3 inflammasome expression in THP-1 cells, all of which were mitigated by butyrate administration. However, these protective effects of butyrate were abrogated by NLRP3 gene overexpression in THP-1. In conclusion, AS-IV can ameliorate sepsis-induced gut inflammation and barrier dysfunction by modulating M1/M2 polarization of gut macrophages, whose underlying mechanism may be restoring gut microbiome and SCFA to restrain NLRP3 inflammasome activation.
参考来源
- Yang T, Xie S, Cao L, et al. ASTRAGALOSIDE Ⅳ MODULATES GUT MACROPHAGES M1/M2 POLARIZATION BY RESHAPING GUT MICROBIOTA AND SHORT CHAIN FATTY ACIDS IN SEPSIS. Shock. 2023. PMID: 37962207. doi:10.1097/SHK.0000000000002262
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。